Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Biosimilar substitution in Massachusetts

Subjects

Biosimilars may now be substituted for brand-name biologics in Massachusetts as long as the pharmacist informs both the prescribing physician and consumer of the change. The Biotechnology Industry Organization, which has been promoting such legislation, said in a statement, that the law, passed in June, “maintains incentives for innovation and promotes a competitive market for biologic therapies.” The first such bill was signed into law in February of last year in Virginia.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Biosimilar substitution in Massachusetts. Nat Biotechnol 32, 709 (2014). https://doi.org/10.1038/nbt0814-709d

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt0814-709d

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing